Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations Using the OmniSeq Test and Creation of a Biobank from Community Cancer Clinics in the United States to Address Disparities in Precision Medicine

NCT05697198 is registered in ClinicalTrials.gov with Labcorp Corporation of America Holdings, Inc as lead sponsor.

NCT NCT05697198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05697198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations Using the OmniSeq Test and Creation of a Biobank from Community Cancer Clinics in the United States to Address Disparities in Precision Medicine
Lead sponsor
Labcorp Corporation of America Holdings, Inc
Phase
Observational
Overall status
Completed
Start date
April 19, 2021
Completion date
December 31, 2024
Enrollment
1,429 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, esophageal cancer, head and neck cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, rhabdomyosarcoma, soft tissue sarcoma, stomach cancer, uterine cancer